Herpes simplex thymidine kinase/ganciclovir (HSVtk/GCV) gene therapy has been used for the treatment of a variety of cancers. Its efficacy is enhanced by the bystander effect that helps overcome the delivery problems commonly observed in current gene therapy. Connexins encode proteins that produce gap junctions, which enable intercellular communication and the bystander effect. We previously demonstrated that decreased Cx 26 expression and loss of gap junctional intercellular communication were associated with human bladder cancer. To investigate the efficacy of the bystander effect in HSVtk/GCV gene therapy, the Cx 26 gene was introduced into UM-UC-3 and UM-UC-14 bladder
Introduction
Each year, more than 50 000 new cases of bladder cancer are detected. 1 Superficial bladder cancers constitute 80% of these neoplasms and are associated with a high rate of tumor recurrence despite treatment consisting of transurethral resection and intravesical chemotherapy or immunotherapy. 2 Tumor progression within 5 years occurs in up to 30-40% of patients with high-risk superficial disease, and 15-34% of patients with superficial bladder cancer die of their cancer. 3, 4 The prognosis for patients with advanced tumors is poor even for patients who receive aggressive multimodal therapy, with only 20-40% of patients with advanced bladder cancer surviving 5 years. 3, 4 Thus, novel treatments are needed to improve the prognosis for patients with bladder cancer.
Connexins (Cxs) encode a family of transmembrane proteins known as gap junctional intercellular communication (GJIC) proteins, which mediate the transfer of ions, metabolites, and small regulatory molecules. 5 Cxs are involved in embryonic development, differentiation, and growth control. 6, 7 In general, the expression of Cxs in [11] [12] [13] [14] Herpes simplex thymidine kinase/ganciclovir (HSVtk/ GCV) gene therapy has been demonstrated to treat effectively various types of cancers in vitro and in vivo. [15] [16] [17] [18] [19] In HSVtk/GCV gene therapy, the toxicity of GCV is extended from HSVtk-transduced cells to adjacent HSVtknegative cells through the so-called bystander effect. Some studies have shown that the bystander effect in HSVtk/GCV gene therapy is mediated by Cx expression and that the exogenous introduction of Cx 26 or Cx 43 enhances the bystander effect. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The bystander effect enhances the efficacy of HSVtk/GCV gene therapy by enabling toxic metabolites to pass to adjacent HSVtknegative cells and helps overcome the current major limitation of gene therapy -the inability to achieve expression of the transgene in all cancer cells in a tumor. 30 The bystander effect has also been shown to facilitate other gene therapy approaches, such as suicide gene therapy involving transfer of the cytosine deaminase gene and tumor growth suppression involving the tumor suppressor gene p53. 31, 32 In this study, we investigated whether the Cx 26 gene increases the bystander effect in HSVtk/GCV gene ther-apy in human bladder cancer using an adenovirus poly-l-lysine (Adv/PLL) conjugate with a multigenic expression plasmid that expresses both the HSVtk and Cx 26 genes. Our data demonstrate the effectiveness of this construct in inducing the bystander effect in two human bladder cancer cell lines that do not express endogenous Cx 26.
Results

Transduction of bladder cancer cells in vitro
The transduction efficiencies of Adv/PLL/pGT60LacZ complexes were examined in UM-UC-3 and UM-UC-14 bladder cancer cells at various multiplicities of infection (MOIs) of viral particles per cell (Table 1) . A high MOI was required to transduce X-gal because the MOI reflected the number of adenoviral particles and not plaque-forming units. Cytotoxicity was observed at MOIs that resulted in у50% of cells expressing the LacZ gene.
The role of the Cx 26 gene in the bystander effect in vitro To examine whether Cx 26 mediates the bystander effect, we infected UM-UC-3 and UM-UC-14 bladder cancer cells with Adv/PLL conjugate without plasmid DNA (control adenovirus), Adv/PLL/pGT60LacZ complexes, or Adv/PLL/pGT60hCx26 complexes at the indicated MOIs, or mock in the presence of culture medium containing 2% fetal bovine serum (FBS). Both Adv/ PLL/pGT60LacZ and Adv/PLL/pGT60hCx26 contain the HSVtk gene ( Figure 1 ). The degree of bystander effectmediated cell killing was determined by measuring cell survival after 5 days of GCV treatment.
The cytotoxicity in cells infected with Adv/PLL/ pGT60hCx26 complexes was significantly greater than that in cells infected with Adv/PLL/pGT60LacZ complexes ( Figure 2 ). In comparison with control adenovirusinfected cells, UM-UC-3 cells infected with Adv/PLL/pGT60hCx26 complexes at 50 MOI exhibited growth inhibition of 76.6% and 80.4% at 10 and 50 g/ml GCV, respectively, whereas cells infected with Adv/PLL/pGT60LacZ complexes showed only 6.5% and 37.9% growth inhibition, respectively (Figure 2a) . In comparison with control adenovirus-infected cells, UM-UC-14 cells infected with Adv/PLL/pGT60hCx26 complexes at 100 MOI under the same condition also exhibited growth inhibition of 41.1% and 51.9% at 10 and 50 g/ml GCV, respectively, whereas Adv/PLL/pGT60LacZ complexes showed growth inhibition of 6.7% and 25.1% ( Figure  2b ). The cytotoxicity produced by Adv/PLL/pGT60hCx26 complexes in UM-UC-3 and UM-UC-14 cells was statistically significant relative to the cytotoxicity produced by Adv/PLL/pGT60LacZ complexes at the same MOI and concentration of GCV (P Ͻ 0.01, Figure 2a, b) . Control adenovirus infection resulted in a minor degree of growth inhibition that was significantly less than that seen after infection with Adv/PLL/pGT60hCx26 or Adv/PLL/pGT60LacZ complexes (Figure 2a, b) . GCV was cytotoxic at a concentration as low as 10 g/ml in UM-UC-3 and UM-UC-14 cells treated with Adv/PLL/pGT60hCx26 complexes but not in cells treated with Adv/PLL/pGT60LacZ complexes at intermediate and low MOIs (Figure 2a, b) .
To examine the effect of Cx 26 as a tumor suppressor, we evaluated cell growth without the addition of GCV. Five days after infection, UM-UC-3 cells infected with Adv/PLL/pGT60hCx26 complexes at 50 and 100 MOI, although not at 25 MOI, showed a growth inhibition of 13% and 29.7%, respectively, compared with the growth of control adenovirus-infected cells (P Ͻ 0.05 at both MOIs, Figure 2c ). The magnitude of growth suppression by Cx 26 alone was much less than that seen with Adv/PLL/pGT60hCx26 complexes in HSVtk/GCV gene therapy. There was no significant growth inhibition of UM-UC-14 cells infected with Adv/PLL/pGT60hCx26 complexes at 100 or 200 MOI (Figure 2d ). 
Detection of Cx 26 and HSVtk gene expression
Functional assay for GJIC of bladder cancer cells
We observed the presence of functional GJIC in UM-UC-3 and UM-UC-14 cells infected with Adv/PLL/ pGT60hCx26 complexes using the scrape-loading lucifer yellow dye transfer assay. Two days after infection with 
In vivo bystander effect of Cx 26 transduced cells in nude mice
To test the effect of Cx 26 on enhancing the bystander effect in vivo, tumorigenicity was assessed in nude mice. Cells infected with either Adv/PLL/pGT60hCx26, Adv/PLL/pGT60LacZ, or Adv/PLL without plasmid DNA were injected into the dorsal flanks of nude mice. The mice were then split into groups with some beginning treatment with GCV 24 h later. Tumorigenicity was assessed 21 days after tumor cell inoculation (Table 2) . UM-UC-3 cells infected with Adv/PLL/pGT60hCx26 resulted in decreased tumor volume but no change in tumor incidence in comparison to cells infected with Adv/PLL/pGT60LacZ. This represents a modest tumor suppressive effect of the CX 26 construct. Similarly, in mice treated with GCV, Adv/PLL/pGT60LacZ decreased tumor volume but not tumor incidence in comparison to
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Adv/PLL without plasmid DNA. This represents the effect of HSVtk/GCV gene therapy. On the other hand, dramatic decreases in both tumor volume and tumor incidence were found in mice treated with GCV and Adv/PLL/pGT60hCx26. These results demonstrate that induction of Cx 26 expression enhances the bystander effect in vivo as well as in vitro.
Discussion
The tools and concepts of gene therapy are being applied to the development of new treatments for human cancers. 33 One example that has been explored in a variety of in vitro and in vivo studies is HSVtk/GCV gene therapy. 34 This efficacy of HSVtk/GCV gene therapy is enhanced by the bystander effect, which helps overcome the limitations of insufficient gene transduction. At this time, the bystander effect appears to be essential for the in vivo success of suicide gene therapy. 27, 29 In vivo experiments have indicated that another advantage of HSVtk/GCV suicide gene therapy is that it elicits an inflammatory immune response that is directed against the tumors. 35, 36 The induced immunogenicity to distant HSVtk-negative tumor cells has been termed the distant bystander effect. 37, 38 When cells become transformed, the expression of functional gap junctions decreases. 10 Cx transfection and GJIC induction lead to a decreased rate of proliferation, increased differentiation, and reversal of the cell-transformation phenotype.
12,39 Cx 43, Cx 32 and Cx 26 knockouts result in heart malfunction, an increased incidence of liver tumors, and malfunction of the placenta, respectively. 40, 41 The tissue-specific expression of Cxs is well documented. 42 For example, Cx 32 is the major gap junction protein that has been detected in human liver and kidney. In contrast, Cx 43 is expressed in fibroblasts, osteoblasts, endothelial cells and mesenchymal tissues, and Cx 
(b) Survival of UM-UC-14 cells, the infection procedure was the same as that in the UM-UC-3 cells except at 50, 100 and 200 MOI. Equal transduction of HSVtk was seen in UM-UC-3 (a) and UM-UC-14 (b) cells infected with Adv/PLL/pGT60LacZ or Adv/PLL/pGT60hCx26 complexes by Western blot analysis. (c and d) Survival of UM-UC-3 (c) and UM-UC-14 (d) cells after infection with mock, control adenovirus, Adv/PLL/pGT60LacZ complexes, or Adv/PLL/pGT60hCx26 complexes but without GCV to examine the direct effect of Cx 26 as a tumor suppressor.
26 is detected in mammary epithelial and urothelial cells. 10, 42 Both Cx 26 and Cx 43 were detected in gastrointestinal tumor cell lines, but only the presence of Cx 43 correlated with the bystander effect. 21, 22 The Cx 26 gene has been shown to function as a tumor suppressor gene in HeLa cells and MCF7 breast cancer cells. 13, 14 Cx 26, 32 and 43 are expressed in normal urothelium, and loss of Cx 26 is found in bladder cancer. 5 Previously, we showed that down-regulation of Cx 26 mRNA expression was associated with functional loss of GJIC in human bladder cancer, but Cx 43 expression did not correlate with GJIC in bladder cancer cells. 10 In this study, we confirmed the lack of Cx 26 expression in the human bladder cancer cell lines UM-UC-3 and UM-UC-14. After introduction of the HSVtk and Cx 26 genes by an Adv/PLL conjugate, we observed Cx 26 expression and a significant extension of the bystander effect in comparison with that associated with introduction of the HSVtk and LacZ genes. GCV was cytotoxic at a concentration as low as 10 g/ml in UM-UC-3 and UM-UC-14 cells treated with Adv/PLL/pGT60hCx26 complexes but not in cells treated with Adv/PLL/pGT60LacZ complexes. In addition, Adv/PLL/pGT60hCx26 infection resulted in the formation of functional gap junctions. Although introduction of Cx 26 alone resulted in growth suppression of UM-UC-3 cells, this effect was significantly less than the cytotoxicity resulting from Cx 26 and HSVtk/GCV gene therapy (ie bystander effect). Our data suggest that gene therapy with Adv/PLL/pGT60Cx26 for bladder cancer is most effective as a diffuser or a dose-reducing factor in combined HSVtk/GCV gene therapy.
The use of an Adv/PLL conjugate with DNA is a simple, rapid, and reproducible system for testing the effect 
Figure 3 Western blot analysis to detect Cx 26 expression in UM-UC-3 and UM-UC-14 bladder cancer cells infected with Adv/PLL/pGT60hCx26 complexes and medium alone (mock) at the indicated MOIs. The molecular weight of Cx 26 is 26 kDa.
of therapeutic gene expression in cancer both in vitro and in vivo. [43] [44] [45] Furthermore, the use of a multigenic expression plasmid containing HSVtk and Cx 26 provided a simple system for both inducing and ensuring the expression of both genes. In the present study, the Adv/PLL conjugate was chemically modified by the covalent attachment of PLL to a replication-defective adenoviral capsid, allowing for direct interaction with DNA. This modified adenovirus can then act as a delivGene Therapy ery vehicle for ionically attached plasmid DNA to PLL. Previously this Adv/PLL conjugate has been used to achieve high-level p53 gene delivery in lung cancer cells in vitro and in vivo. 46 and efficient gene transfer into various cancer cell lines, including lung, cervical, colon, and esophageal cancer cell cells, as well as into fibroblasts, normal human bronchial epithelial cells, and normal human skeletal cells in vitro. 44, 45 However, analysis of in vitro transduction efficiencies using X-gal (LacZ) staining revealed low efficiency compared with that of Cx 26 expression at the same MOI shown by immunofluorescence. This difference may reflect the low sensitivity of Xgal (LacZ) staining in comparison with the sensitivity of immunostaining. 47 In fact, we found significantly increased cytotoxicity mediated by the bystander effect in HSVtk/GCV gene therapy after introduction of the HSVtk and Cx 26 genes together compared with the cytotoxicity seen after introduction of the HSVtk gene and LacZ genes in vitro and in vivo. Similarly, combination therapy of HSVtk and Cx 43 compared with an isogenic HSVtk vector significantly induced the bystander killing effect in Cx-negative L929 fibrosarcoma cells in vitro and Cx-positive U-87 MG human glioblastoma cells in vivo. 48 The recombinant adenovirus systems can efficiently deliver genes both in vitro and in vivo but require a helper cell line and homologous recombination to generate a recombinant adenovirus. As a result, it may take several months for these labor-intensive and time-consuming techniques to generate the recombinant adenovirus vector. The Adv/PLL conjugate system provides a simple method for delivering and testing therapeutic gene expression in cells before the development of more traditional gene therapy vectors such as adenoviral or retroviral vectors. These data using an Adv/PLL conjugate indicate that restoring Cx 26 function in bladder cancer cells increases the effectiveness of HSVtk/GCV gene therapy.
This is the first demonstration of the bystander effect in bladder cancer. The functional status, regulation, and expression of Cx 26 should be considered in the design of HSVtk/GCV gene therapy for bladder cancer.
Materials and methods
Cell lines and plasmid vectors
Human bladder cancer cell lines UM-UC-3 and UM-UC-14 were cultured in Dulbecco's modified Eagle's medium containing 10% heat-inactivated FBS at 37°C in an atmosphere of 5% CO 2 . 49 We used the multigenic expression plasmid vectors pGT60LacZ and pGT60hCx26 (obtained from InvivoGen, San Diego, CA, USA; Figure 1 ). The pGT60lacZ contains the HSVtk gene under the control of the complete human immediate-early cytomegalovirus (hCMV) promoterenhancer, and the ␤-galactosidase (LacZ) gene under the control of the elongation factor-1␣ (EF-1␣)/human T cell leukemia virus (HTLV) type 1 long terminal repeat (LTR) hybrid promoter. The pGT60hCx26 contains the HSVtk
Figure 4 Immunolocalization of Cx 26 in UM-UC-3 (b) and UM-UC-14 (d) bladder cancer cells after exogenous introduction of the Cx 26 gene by infection with Adv/PLL/pGT60hCx26 complexes compared with UM-UC-3 (a) and UM-UC-14 (c) cells infected with Adv/PLL/pGT60LacZ complexes at 50 and 100 MOIs, respectively (original magnification × 400).
gene and substitutes the human Cx 26 gene for the LacZ gene.
Adv/PLL/DNA complex formation and in vitro administration
The Adv/PLL conjugate was produced as described previously. [44] [45] [46] For the in vitro administration of Adv/PLL/DNA complexes, 10 g DNA in 250 l HBS (150 mm NaCl, 20 mm Hepes, pH 7.3) was added to 1 × 10 10 modified adenoviral particles in 333 l HBS and incubated at room temperature for 30 min. An additional 250 l HBS was then added, and the mixture was incubated for another 30 min at room temperature. The final concentrations of the Adv/PLL/DNA complexes in 833 l were 0.012 microgram per microliter of DNA and 1.2 × 10 7 virus particles per microliter of adenovirus. The cells were infected with Adv/PLL/DNA complexes according to the MOI, defined as the number of modified adenovirus particles per cell.
Uptake and expression of Adv/PLL/DNA complexes in cells UM-UC-3 and UM-UC-14 bladder cancer cells were seeded in 35-mm six-well plates. Twenty-four hours after plating, the number of cells was determined, and the cells were infected with Adv/PLL/DNA complexes at concentrations ranging from 25 to 500 MOI or mock in the presence of culture medium containing 2% FBS for 2 h at 37°C. Forty-eight hours after infection, in vitro transduction efficiencies were determined by X-gal (Sigma, St Louis, MO, USA) staining. 50 Blue-staining cells were counted to determine the transduction efficiency. For protein analysis, cancer cells were infected with Adv/PLL/pGT60hCx26 complexes at 25, 50, 100 or 200 MOI, as described above. Two days after infection, the cells were harvested in lysis solution containing 50 mm Tris-HCl (pH 7.5), 1 mm EDTA, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 10% glycerol, 1 m pepstatin, 1 g/ml aprotinin, 100 g/ml phenylmethylsulfonyl fluoride, and 1 g/ml leupeptin. Western analysis was performed as described previously. 51 Immunoblotting was carried out using a rabbit polyclonal antibody to Cx 26 (Zymed) and a mouse monoclonal antibody to HSVtk (provided by Dr WC Summers, Yale University, New Haven, CT, USA), followed by incubation with horseradish peroxidase-conjugated secondary antibody (goat anti-rabbit or anti-mouse; Santa Cruz Biotechnology, Santa Cruz, CA, USA). A human monoclonal antibody to ␤-actin (Boehringer Mannheim Biochemica, Mannheim, Germany) was used as an internal control. Protein-antibody complexes were detected by an enhanced chemiluminescence system (ECL-Plus; Amersham, Piscataway, NJ, USA) on radiographic film.
Functional cell communication assay GJIC was measured by the scrape-loading lucifer yellow dye transfer assay. 52 UM-UC-3 and UM-UC-14 bladder cancer cells (5 × 10 4 and 1 × 10 5 cells, respectively) were plated in 12-well plates for 24 h and then infected with Adv/PLL/pGT60hCx26 or Adv/PLL/pGT60LacZ complexes as described above. Two days after infection, the culture medium was removed from confluent cultures, and cells were washed twice with PBS. Monolayers were then covered with 200 l of 0.05% lucifer yellow (Molecular Probes, Eugene, OR, USA) and scratched with a 20-gauge needle. The dye solution was removed after incubation for 5 min, and cells were washed twice with PBS. The cells were observed with a fluorescenceinverted microscope and photographed to document the degree of dye transfer.
In vivo experiments UM-UC-3 cells were infected in vitro as described above with Adv/PLL conjugate without plasmid DNA (control adenovirus), Adv/PLL/pGT60LacZ complexes, or Adv/ PLL/pGT60hCx26 complexes at 50 MOI. To determine the tumor growth, 4-to 6-week-old male nude mice (nu/nu; Harlan, Indianapolis, IN, USA) were used to inject 1 × 10 6 tumor cells subcutaneously 24 h after infection. Twenty-four hours after tumor cell inoculation, mice received i.p. injection of GCV (10 mg/kg; twice a day) for 6 days. Tumor formation was measured using a linear caliper. The tumor volume was calculated using the equation, vol (mm 
Statistical analysis
The results are presented as mean ± standard deviation (s.d.). Fisher's exact test and Student's t test were used with P Ͻ 0.05 considered statistically significant.
